Antitumor Effects of an Imidazoquinoline in Renal Cell Carcinoma

Urology

Volumn 73, Issue 5, 2009, Pages 1156-1162

  Schwartz, Michael J ^a   Liu, Huixian ^a   Hwang, David H ^a   Kawamoto, Hideki ^a   Scherr, Douglas S ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOQUINOLINE DERIVATIVE; TOLL LIKE RECEPTOR 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN A 498; CELL STRAIN CAKI 1; CELL STRAIN CAKI 2; CELL STRAIN RENCA; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO CULTURE; KIDNEY CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOPSY, NEEDLE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; QUINOLINES; SENSITIVITY AND SPECIFICITY; TOLL-LIKE RECEPTOR 7;

EID: 65049090350     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.02.010     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Lam J.S., Leppert J.T., Figlin R.A., et al. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Cur Urol Rep 6 (2005) 7-18
3. Milowsky M.I., and Nanus D.M. Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am 30 (2003) 601-609
4. Yagoda A., Abi-Rached B., and Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22 (1995) 42-60
5. Halperin E.C., and Harisiadis L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51 (1983) 614-617
6. DiBiase S.J., Valicenti R.K., Schultz D., et al. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol 158 (1997) 746-749
7. Cannady S.B., Cavanaugh K.A., Lee S.Y., et al. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys 58 (2004) 253-258
8. Vogelzang N.J., Priest E.R., and Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 148 (1992) 1247-1248
9. de Riese W., Goldenberg K., Allhoff E., et al. Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 23 (1991) 13-25
10. Miller G.A., Pontes J.E., Huben R.P., et al. Humoral immune response of patients receiving specific active immunotherapy for renal cell carcinoma. Cancer Res 45 (1985) 4478-4482
11. Radmayr C., Bock G., Hobisch A., et al. Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int J Cancer 63 (1995) 627-632
12. 2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
13. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 353 (1999) 14-17
14. 2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
15. McDermott D.F. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 13 2 pt 2 (2007) 716s-720s
16. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
17. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
18. Seya T., Akazawa T., Uehori J., et al. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 23 (2003) 4369-4376
19. Okamoto M., and Sato M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest 50 (2003) 9-24
20. Hemmi H., Kaisho T., Takeuchi O., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196-200
21. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
22. Smith E.B., Schwartz M., Kawamoto H., et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 177 (2007) 2347-2351
23. Schon M., Bong A.B., Drewniok C., et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95 (2003) 1138-1149
24. Horiguchi A., Sumitomo M., Asakuma J., et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Can Res 10 (2004) 8648-8655
25. Lebwohl M., Dinehart S., Whiting D., et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 50 (2004) 714-721
26. Geisse J., Caro I., Lindholm J., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 505 (2004) 722-733
27. Bong A.B., Bonnekoh B., Franke I., et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205 (2002) 135-138
28. Schon M.P., Wienrich B.G., Drewniok C., et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 122 (2004) 1266-1276
29. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
30. Witt P.L., Ritch P.S., Reding D., et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 53 (1993) 5176-5180